Skip to main content
Back
KRYS logo

Krystal Biotech, Inc.

Data quality: 100%
KRYS
NASDAQ Healthcare Biotechnology
$247.09
▼ $2.99 (-1.20%)
Mkt Cap: 7.22B
Day Range
$243.18 $252.83
52-Week Range
$122.80 $298.30
Volume
271,518
50D / 200D Avg
$269.80 / $199.95
Prev Close
$250.08

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E 35.3 0.4
P/B 5.9 2.9
ROE % 18.9 3.7
Net Margin % 52.6 3.9
Rev Growth 5Y % 10.0
D/E 0.0 0.2

Analyst Price Target

Hold
$311.00 +25.9%
Low: $224.00 High: $371.00
Forward P/E
32.5
Forward EPS
$7.70
EPS Growth (est.)
+0.0%
Est. Revenue
530 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $27.11
$20.97 – $34.60
1.5 B 1
FY2029 $20.30
$15.70 – $25.90
1.1 B 1
FY2028 $13.46
$8.34 – $27.13
900 M 5

Key Takeaways

Earnings grew 129.74% over the past year
ROE of 18.91% — decent returns on equity
Net margin of 52.64% shows strong profitability
Debt/Equity of 0.01 — conservative balance sheet
Generating 188.91M in free cash flow
P/E of 35.26 — premium valuation

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)33.94%
Earnings (1Y)129.74%
FCF Growth (3Y)N/A

Quality

Return on Equity
18.91%
ROIC9.84%
Net Margin52.64%
Op. Margin41.45%

Safety

Debt / Equity
0.01
Current Ratio9.95
Interest Coverage0.00

Valuation

P/E Ratio
35.26
P/B Ratio5.92
EV/EBITDA41.76
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 33.94% Revenue Growth (3Y) 177.04%
Earnings Growth (1Y) 129.74% Earnings Growth (3Y) 332.86%
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 389.13M Net Income (TTM) 204.83M
ROE 18.91% ROA 15.36%
Gross Margin 92.61% Operating Margin 41.45%
Net Margin 52.64% Free Cash Flow (TTM) 188.91M
ROIC 9.84% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.01 Current Ratio 9.95
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 35.26 P/B Ratio 5.92
P/S Ratio 18.56 PEG Ratio 0.27
EV/EBITDA 41.76 Dividend Yield 0.00%
Market Cap 7.22B Enterprise Value 6.74B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 389.13M 290.52M 50.70M 0.0 0.0
Net Income 204.83M 89.16M 10.93M -139.98M -69.57M
EPS (Diluted) 6.84 3.00 0.39 -5.49 -3.13
Gross Profit 360.36M 270.45M 47.61M 0.0 0.0
Operating Income 161.30M 65.70M -109.73M -145.20M -68.28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.33B 1.06B 818.36M 558.45M 626.30M
Total Liabilities 114.23M 109.46M 39.71M 36.22M 32.72M
Shareholders' Equity 1.22B 946.38M 778.64M 522.23M 593.58M
Total Debt 9.34M 7.26M 8.09M 8.93M 8.02M
Cash & Equivalents 496.30M 344.87M 358.33M 161.90M 341.25M
Current Assets 1.02B 742.05M 587.91M 383.78M 442.27M
Current Liabilities 102.94M 102.00M 33.09M 28.85M 25.74M